High-throughput screening of RNAi libraries has become an essential part of functional analysis in academic and industrial settings. The transition of a cell-based RNAi assay into a 384-well format requires several optimization steps to ensure the phenotype being screened is appropriately measured and that the signal-to-background ratio is above a certain quantifiable threshold. Methods currently used to assess small interfering RNA (siRNA) efficacy after transfection, including quantitative PCR or branch DNA analysis, face several technical limitations preventing the accurate measurement of mRNA levels in a 384-well format. To overcome these difficulties, the authors developed an approach using a viral-based transfection system that measures siRNA efficacy in a standardized 384-well assay. This method allows measurement of siRNA activity in a phenotypically neutral manner by quantifying the knockdown of an exogenous luciferase gene delivered by a lentiviral vector. In this assay, the efficacy of a luciferase siRNA is compared to a negative control siRNA across many distinct assay parameters including cell type, cell number, lipid type, lipid volume, time of the assay, and concentration of siRNA. Once the siRNA transfection is optimized as a 384-well luciferase knockdown, the biologically relevant phenotypic analysis can proceed using the best siRNA transfection conditions. This approach provides a key technology for 384-well assay development when direct measurement of mRNA knockdown is not possible. It also allows for direct comparison of siRNA activity across cell lines from almost any mammalian species. Defining optimal conditions for siRNA delivery into mammalian cells will greatly increase the speed and quality of large-scale siRNA screening campaigns. (Journal of Biomolecular Screening 2007:546-559) 
INTRODUCTION
H IGH-THROUGHPUT SCREENING (HTS) of small interfering RNAs (siRNAs) is rapidly becoming a driver of target discovery and validation in the pharmaceutical industry. One challenge of a genomics-based HTS using siRNAs is the need for maximizing siRNA activity while minimizing cellular toxicity. This is a particular challenge as optimization of cell-based assays must be done in a miniaturized format to increase both throughput and efficiency. To address this challenge, we have designed a method for optimizing siRNA delivery into cells under miniaturized conditions prior to carrying out a large-scale screening campaign. This approach uses a standard readout that can be applied to a large number of cell lines to determine the optimal conditions and cell type for carrying out specific phenotype-based siRNA screens.
Most large-scale siRNA libraries are screened in a 384-well format, requiring miniaturization of a cell-based assay. However, most complex cell-based assays are developed in 96-well plates, or larger area formats, and have to be properly optimized in a 384-well format. This optimization method is of particular importance when a well-validated siRNA positive control is not known because fluorescent-based reporters and quantitative PCR (QPCR) are difficult to extend to 384-well formats. As well, it is not clear if results from optimized 96-well assays will translate to higher density plate formats. siRNA screens can be optimized in several ways: based on a phenotype induced from a biologically relevant positive control siRNA, by analyzing the siRNA against a yellow fluorescent protein fusion construct of the target gene, 1 or, most commonly, by mRNA measurement, usually done by quantitative real-time PCR. Although these approaches have been successful, they also have several limitations. Optimization based on phenotype does not rely on siRNA efficacy and does not represent the best conditions for all siRNAs. It is possible that offtarget effects might contribute to the phenotype under study. Furthermore, data obtained for a positive control in a phenotypic readout may not be readily comparable to data obtained in assays using multiple cell lines requiring different control siRNAs. It is not clear if optimization of gene transfer conditions using 1 cellular phenotype will provide the best condition for gene knockdown when measuring additional phenotypes. In this regard, 1 concern in siRNA experiments is that a siRNA-induced phenotype might be due to a combinatorial effect of the siRNA transfection procedure as well as the reduction of a target gene's mRNA levels. Therefore, measurement of siRNA efficacy would best be done in a manner independent of the phenotype being measured (referred to here as a phenotypically neutral approach). The phenotypically neutral approach is defined as targeting an exogenous reporter, such as luciferase (pGL3) or green fluorescent protein (GFP), rather than an endogenous gene. In this way, the optimized siRNA transfection conditions are determined strictly by the knockdown of the overexpressed reporter and therefore avoid complicating factors associated with targeting endogenous genes (i.e., mRNA abundance, siRNA efficiency, effects on cell viability, cell line variation).
To quantify our ability to deliver active siRNAs into mammalian cells, we describe a method to directly compare the efficiency of siRNA knockdown under a variety of assay conditions and cell lines. The assay involves the cellular transduction of a luciferase-expressing lentivirus followed by a multiparameter transfection of luciferase and GFP-directed siRNAs. The lentivirus in combination with the vesicular stomatitis virus (VSV-G) envelope was chosen because of its ability to transduce almost any cell, dividing or nondividing, that contains phospholipid. siRNA efficacy is quantified in a phenotypically neutral way by measuring the knockdown of the exogenously expressed luciferase. This assay can be used in virtually any mammalian cell type, allowing for a uniform method to compare different cell lines for transfectability in siRNA experiments. From the optimized conditions defined by luciferase knockdown, the phenotypic assay can be performed with biologically relevant positive controls, when available, to verify the optimization of siRNA transfection conditions. Maximizing siRNA efficacy prior to developing a phenotype-based screen should increase the efficiency of target message knockdown, resulting in a better signal-to-noise ratio. Using the optimized siRNA transfection conditions found in SKOV3 cells, multiple siRNAs against several distinct endogenous genes were found to knock down mRNA levels by 60% to 80%. Therefore, the 384-well optimized transfection conditions translate into significant mRNA knockdown of various target genes. More important, this phenotypically neutral approach will allow for more rapid development of robust 384-well siRNA screens and the ability to define the most effective siRNA transfer conditions for cell-based assays in miniaturized formats.
MATERIALS AND METHODS

Plasmid construction
The luciferase gene (pGL3; Promega, Madison, WI, or Genbank U47295) was cloned into the pLLB3-GW-Kan lentivirus vector (gift from B. Latario) at the restriction sites Xba1 and Nhe1. The new sequence-verified vector is named pLLB3-GW-Kan-pGL3.
Viral packaging protocol
Plate HEK293T cells at 7.8 × 10 5 on poly-d-lysine plates (6well plates; Becton Dickinson, Franklin Lakes, NJ, or Fisher, Pittsburgh, PA) in 2 ml of DMEM (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS) and no antibiotics, and incubate at 37 °C, 5% CO 2 , overnight. Mix 1.5 µg of pLP2, 1.5 µg of pLP1, and 0.3 µg of pLP/VSV-G packaging plasmids (Virapower; Invitrogen) diluted in Opti-MEM-I into a 15-ml Falcon roundbottom tube (Becton Dickinson). Add 3 µg of pLLB3-GW-Kan-pGL3 lentiviral DNA diluted in Opti-MEM-I to the tube, and bring the volume to 282 µl with Opti-MEM-I. Add 18 µl Fugene 6 (Roche, Basel, Switzerland) to the tube (added last, directly into the media). The final reaction volume is 300 µl. Mix and incubate at room temperature for 30 min. Add 300 µl to each well of the 293T cells plated the previous day, and incubate the cells at 37 °C, 5% CO 2 , overnight. On the next day, aspirate media and replace with 2 ml of fresh DMEM containing 10% FBS and 1% Pen-Strep (Invitrogen), and incubate overnight. The following day, collect the supernatant at 48 h posttransfection and replace with 2 ml of complete media. At 72 h after transfection, collect the supernatants and pool with the 48-h collection. Filter viral supernatants using a 0.45-µM polyvinylidene difluoride Durapore membrane (Millipore, Billerica, MA) to remove any nonadherent packaging cells, and store as -80 °C aliquots until use.
Viral transduction protocol
For a bulk viral (6-well) transduction in SKOV3, A549, Hela, MDA-MB-231, and Panc 4.03 cells, plate cells at 200,000 per well in a 6-well dish. The following day, replace media with 1.5 ml of complete growth media containing 8 µg/ml polybrene (Sigma, St. Louis, MO) and 10 mM HEPES (Gibco, Carlsbad, CA). Add 190 µl of virus, and spin cells at 2100 rpm (1000g) for 1.5 h. Optimal conditions for viral transduction will vary from cell line to cell line. However, because of the high expression of the luciferase reporter, optimization of this step is not likely to be critical. Incubate for at least 3 h before siRNA transfection (a 24h incubation with the virus is standard, but there is no difference in performing siRNA transfection after a 3-h incubation with virus).
siRNA transfection
Mix each lipid reagent with 4 µl of Opti-MEM-I in a 384-well tissue culture plate, add 206 nM siRNA in 4 µl of Opti-MEM-I, mix with lipid reagent, and incubate for 30 min to allow siRNA/lipid complexes to form. The concentration of siRNA used in this analysis was set at 25 nM. If manipulation of the siRNA concentration was necessary, this would be the step to construct siRNA dilutions. Wash the luciferase-transduced cells twice in phosphate-buffered saline, trypsinize the cells, count, and dispense into 384-well plates. For a forward transfection, add the complex to cells that were plated 24 h earlier in 25 µl of complete medium. For a reverse transfection, add 25 µl of cells onto tissue culture that contains the siRNA/lipid complex using an automated bulk liquid-dispensing device (i.e., Multidrop), and incubate for 72 h. Each cell line is empirically tested by analyzing 2 cell densities per well ( Table 1) . Assay cells for luciferase activity using the Bright-Glo reagent (Promega) or cell viability using CellTiter-Glo cell viability (Promega). All graphical representation of the data is from at least 3 independent experiments, with the calculated average and standard deviation presented in the figures.
siRNA stocks
Diluted Dharmacon stock siRNAs (GFP) (cat# P-002102-01-05) target sequence 5′-GCG ACG TAA ACG GCC ACA AGT TC -3′ and Dharmacon luciferase (pGL3) siRNAs high silencer (cat# D-002050-01-05) target sequence 5′-GAT TAT GTC CGG TTA TGT ATT -3′, medium silencer (cat# D-002050-02-20) target sequence 5′-CTG AAT ACA AAT CAC AGA A TT -3′, low silencer (cat# D-002050-03-20) target sequence 5′-TCC GGA AGC GAC CAA CGC C TT -3′, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (cat# MQ-004253-01), mevalonate (diphospho) decarboxylase (MVD) (cat# MQ-006748-00), phosphatidylinositol 4-kinase catalytic β polypeptide (PIK4CB) (cat# MQ-006777-02), pGL2 luciferase (cat# D-001100-01-05), alkaline phosphatase and (cat# MQ-008658-00) in 4 µl of Opti-MEM-I to a final concentration of 206 nM in a 384-well PCR plate for a forward transfection or directly onto 384 tissue culture plates (Greiner Bio-One, Kremsmünster, Austria) for a reverse transfection (final concentration of 25 nM). siRNAs tested for the QPCR studies included caspase-8 (cat# M-003466-04) and MKSTYX (cat# M-008031-01) as Dharmacon SMARTpools and TNFRSF1A (cat# MQ-005197-00), YARS (cat# MQ-011498-00), and TRIB3 (cat# MQ-003754-01) as individual Dharmacon duplex siRNAs.
QPCR
Two wells transfected with siRNAs were pooled together, and the mRNA was isolated using the RNeasy96 kit (Qiagen, Venlo, the Netherlands). Preps were DNAse 1 treated twice for 15 min each. cDNA was generated using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). cDNA was oligo dT25 (Sigma Genosys) primed. The buffer (Roche) was supplemented with MgCl 2 (Ambion, Foster City, CA) as follows: 10× buffer at 10 µl, 1 M MgCl 2 at 0.55 µl, 50 µM oligo dT25, 100 mM dNTPs at 4 µl, RNasIn, 20 U/µl at 1 µl, Multiscribe 50 U/µl at 5 µl, ddH 2 O at 12.45 µl, and RNA at 67 µl for a total volume of 100 µl. The cDNA was quantified using primers designed in house (Sigma) using SYBR ® Green on an Applied Biosystems 7900HT. The transcripts analyzed by QPCR included caspase-8 (NM_001228) GGTCACTTGAAC-CTTGGGAA and GAACTTGAGGGAGGCCAGAT at 203 to 328: crossing a 32347 bp intron at 229, MKSTYX (NM_016086) ACATCCTGAAAGGGGGCTAT and GCAC-GATTTCAATGGGGTAT at 716 to 836: crossing a 8333 bp intron at 795, TNFRSF1A (NM_001065) GCTTCAGAAAAC-CACCTCAGACA and ATGCCGGTACTGGTTCTTCCT at 551 to 662, YARS (NM_003680) GCCCTGAAGAGAAACTGCAC and GGGCACAAAGTAAGCCACAT at 804 to 953: crossing a 6128 bp intron at 845, TRIB3 (NM_021158) TCAAGCTGT-GTCGCTTTGTC and CTTGTCCCACAGGGAATCAT at 1053 to 1163: crossing a 4616 bp intron at 1090.
RESULTS
Viral protocol optimization
The pLL3.7-GFP vector was used for viral protocol optimization to check for both transduction efficiency and stability of expression over time. The pLLB3-GW-Kan vector was used as the backbone (after selectable marker and enzyme site modification) to clone in the luciferase gene to create pLLB3-GW-Kan-pGL3. The vectors are shown in Figure 1 .
The protocols for viral transduction were tested in SKOV3 cells to analyze the transduction efficiency of the GFP and luciferase-expressing lentivirus. The GFP virus was introduced into SKOV3 cells, and GFP fluorescence was examined over time. After 24 h, >70% of the cells were transduced, as judged by fluorescence microscopy and the intensity of the GFP signal intensity increased over time ( Fig. 2A) . The luciferase virus was also transduced into SKOV3 cells, and luciferase was measured over a 4-day time course ( Fig. 2B) . Luciferase expression of the transduced cells peaked at 48 h but remained stable up to 96 h. These results confirmed that the luciferase virus used in these studies was functional and that the luciferase expression was stable over time. The 1st step in developing the viral transduction assay was to optimize the amount of virus needed for the bulk transduction. To test this, 6-well plates were transduced with varied doses of the luciferase virus, and the transduced cells were plated in the 96-well format. For the siRNA transfection in SKOV3 cells, several parameters including time (only 72 h shown), cell number, and volume of viral supernatant were varied ( Fig. 3A, B ). The luciferase virus was varied from 48 to 190 µl to find the best volume-to-phenotype ratio because the viral titer (multiplicity of infection) was not quantified on the pooled stocks. The luciferase knockdown efficiency was compared between the GFP and luciferase siRNAs after transfection using 0.28 µl of Dharmafect 2. There was a dose-dependent correlation between the volume of viral supernatant used and luciferase signal, which was cell number dependent. The more densely the cells were plated and the higher the volume of virus used, the greater the luciferase signal. The minimal amount of virus needed to see a good signal-to-background ratio after siRNA transfection (70-fold) was 190 µl/well (6 well) at 72 h using 6000 SKOV3 cells/well (96 well) ( Fig. 3B) . Based on these results, the 190-µl/well volume was used for follow-up transductions.
Similar experiments were also carried out in a 384-well format ( Fig. 3C, D) . The volume of lipid reagent added to the 384well siRNA transfection was one fourth of the 96-well format, or 0.07 µl of Dharmafect 2. For both 96-and 384-well formats, 190 µl of virus per well was used for the bulk transduction, which was significantly knocked out after a 72-h luciferase siRNA transfection. The resulting signal-to-background ratio was 25fold in the 384-well format at 1500 cells/well for 72 h (Fig. 3D) . Knowing the optimal conditions for bulk viral transduction that could be phenotypically measured in both 96-and 384-well formats, we proceeded to optimize siRNA transfection conditions.
siRNA transfection optimization
The 1st step for siRNA transfection optimization was to analyze several lipids using the manufacturer's recommended volumes ( Table 2) . Starting with the optimized viral transduction conditions, analysis of siRNA efficacy across multiple parameters in a 384-well format was analyzed in the SKOV3 cells. The manufacturer's recommended lipid volume in the 96-well format was divided by 4 for the 384-well transfections. The lipids were compared at 72 h at 2 cell densities, using both luciferase and GFP siRNAs (Fig. 4A) . The light units (luciferase activity, Bright-Glo assay) obtained from each transfection vary across condition, but the overall variance is small and correlates with increased cell density (Fig. 4A) . Plotting the data as fold change (Fig. 4B) , it is clear that 2 lipids, Dharmafect 2 and 4, outperformed the others as measured by luciferase knockdown (GFP/luciferase siRNAs) in the SKOV3 cell line. For Dharmafect 2 and 4, the signal-to-background ratios were significantly better than the other lipid reagents, suggesting that the siRNA efficacy under these conditions is superior. This is an important observation because it demonstrates that this assay can distinguish between the different lipids' ability to deliver siRNAs into SKOV3 cells. In addition, when new transfection reagents become available, this assay will be used to distinguish performance within a panel of lipids as siRNA delivery reagents. To be sure the drop in the luciferase signal after lipid treatment was not due to increased cell toxicity, the 6 lipids were tested at their optimal siRNA transfection concentration in SKOV3 cells using GFP siRNAs after luciferase virus transduction. Measuring adenosine triphosphate as a readout for viable cells, lipid transfection affected only viability as compared to untreated cells (no lipid), approximately 2-fold (data not shown). The differences in viability between the cells treated with lipid/siRNA complexes were not statistically significant between the different lipids.
siRNA efficacy analysis
In addition to lipid optimization, it is also important that the assay can distinguish between siRNAs with different efficacies against a respective target. The efficacy of siRNAs can be influenced by several factors including the quality of the siRNA sequence, off-target effects, the chemical preparation, the purity of the siRNAs, and the lipid reagent used. To test for siRNA target-specific efficacy, the high, medium, and low silencer Dharmacon luciferase siRNAs, which differ in their published efficacy, were analyzed in luciferase-expressing cells. As well, a collection of negative control siRNAs was also analyzed to provide a benchmark for off-target effects on luciferase knockdown. The high silencer siRNA was reported by Dharmacon to inhibit relative firefly luciferase activity by ∼95%, the medium silencer by ∼70%, and the low silencer by <10%. SKOV3 cells were transduced with luciferase lentivirus and transfected with luciferase siRNAs using Dharmafect 4 for 72 h (Fig. 5A) . The lipid transfection had no effect on viability, with or without siRNAs (Fig. 5B) . There is a clear difference in performance between the luciferase siRNAs as predicted, demonstrating that this assay is able to distinguish siRNAs with different efficacies against the luciferase target message (the low silencer siRNA could inhibit ∼10% of the luciferase signal as compared to the average of the negative control siRNAs, whereas the high silencer could inhibit ~98% of the signal). These results suggest that the optimized conditions used in this assay will be sensitive enough to distinguish between siRNA target-specific efficacy and likely resolve fine differences in transfection conditions. The resolution of subtle differences in siRNA transfection efficiency can result in significant improvements of siRNA delivery and ultimately better signalto-background ratios when measuring phenotype. Finally, this siRNA optimization strategy was tested across several different cell lines in culture. A549, Hela, MDA-MB-231, and Panc 4.03 cells were all transduced with the luciferase virus and transfected with luciferase or GFP siRNAs for 72 h using the 384-well optimization protocol (see the "Materials and Methods" section). Figure 6A, B, C, and D represent the raw luciferase (Bright-Glo) and viability (CellTiter-Glo) data across all the assay conditions. It is important to note that there is a clear correlation between viability and the loss of luciferase signal over the lipid dose response. All of the lipids are toxic at higher volumes, with the exception of Oligofectamine, which had a toxicity range ≤2fold. Summarizing the data as fold change (GFP/pGL3), it becomes clear what lipid condition has the best siRNA efficacy for each individual cell line (Fig. 6E) . In each cell line, the optimal conditions based on time (only 72 h shown), cell number (only 1 cell density shown), reagent to use, and volume of reagent were identified. siRNA concentration was not varied for these studies because our screening collection was optimized at 25 nM. Of the few cells lines that were tested, our data suggest that this optimization strategy is effective at rapidly defining optimal transfection conditions for cellular siRNA delivery in a 384-well format using different cell types ( Table 3) .
Analysis of optimized lipid conditions using QPCR
To determine whether the optimized siRNA transfection conditions in SKOV3 cells obtained via the luciferase assay also produced robust reduction of endogenous mRNAs, several genes were targeted using SMARTpool and multiple independent duplex siRNAs. Caspase-8 and MKSTYX were targeted using a SMARTpool siRNA (n = 8), and the mRNA was quantified using QPCR and normalized to a control siRNA targeting GFP. Both caspase-8 and MKSTYX were knocked out by >80%, indicating that siRNA delivery into the cell was robust and resulted in significant mRNA reduction (Fig. 7A) . siRNAs were also designed against 3 additional genes as multiple independent duplex siRNAs. Each individual siRNA was transfected into 2 wells, and the 2 wells were pooled together for QPCR analysis. All of the siRNAs could knock down the respective target message by ≥60% and some by >80% (Fig. 7B) . Taken together, both experiments clearly demonstrate that the siRNA transfection conditions optimized using the luciferase assay system resulted in mRNA knockdown of several endogenous target genes.
DISCUSSION
We have developed a standardized high-throughput assay for optimizing siRNA delivery into mammalian cells based on the inhibition of an exogenous luciferase gene. This method is designed to determine optimal siRNA transfection conditions by quantifying the reduction of luciferase enzyme activity as a surrogate for mRNA knockdown. Using optimized viral transduction and siRNA transfection techniques, we were able to assess the conditions necessary for the efficient delivery of siRNA into several cell lines of interest. Standardization of this optimization step during assay development will greatly improve the ability to measure siRNA efficacy in a 384-well format. As a result, we predict this level of assay optimization will translate into better knockdown of target genes (both high and low abundance) and result in more robust phenotypic readouts in cell-based assays.
This assay is sensitive enough to measure differences in transfection efficiencies of various lipid reagents (Fig. 4A, B) . This is an important aspect of the system because it allows for the analysis of many lipids in parallel, as well as the ability to analyze and compare the performance of new transfection reagents as they become available. The differentiation of lipid performance in a particular cell line will afford us the opportunity to build a database of optimized transfection techniques, matching cell lines with lipid reagents to improve on our screening infrastructure ( Table 3) .
The assay can also differentiate between siRNAs with different efficacies against a target message, as tested with the luciferase high, medium, and low silencer siRNAs from Dharmacon (Fig. 5) . Among the key problems with siRNA potency is assessing on-target efficacy and the more difficult task of determining off-target effects. 2 These effects can lead to false positives in the case of off-target siRNAs and false negatives in the case of poor on-target siRNAs. 3 The fact that this assay can easily distinguish between siRNAs of various potencies provides confidence that this optimization approach is sensitive enough to pick up small differences in transfection efficiency and allow for the determination of the minimal amounts of siRNA needed to ensure good gene inhibition. Although siRNA concentration was not varied in these experiments, we have determined that 25 nM is a sufficient concentration to inhibit most high-and lowabundance targets we have analyzed (data not shown). These studies were designed to better optimize siRNA transfection conditions to reduce the off-target effects associated with siRNAs. One of the key problems with siRNA transfection, in contrast to other transfections, such as cDNA, is that siRNA can bind to transcripts other than the intended target. 4, 5 Off-target rates are associated with several experimental parameters including transfection conditions, which contribute to the combinatorial effects of the lipid reagent being used or the quality of the siRNA sequence design, both of which are known to affect cellular viability and expression of other genes. 6, 7 This assay optimization system was designed to control for off-target effects in several ways. The 1st way was to analyze multiple independent siRNAs directed to luciferase (Fig. 5) , which have been previously shown to be efficacious (Dharmacon, data not shown) as compared to more than 1 negative control siRNA. Second, we used the optimized lipid transfection conditions and analyzed multiple independent siRNA duplexes targeting several distinct endogenous genes ( Figs. 5 and 7) . Measuring mRNA knockdown compared to the GFP siRNA, each of the sequences was able to knock down mRNA levels by ≥60%. One way to ensure that a siRNA is having an on-target effect is to validate mRNA knockdown with multiple independent siRNA reagents. In this way, one can have much more confidence that the gene of interest is being suppressed. To be ( Fig. 6 continued) 
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Time ( comprehensive when addressing off-target effects, a microarray experiment would have to be run for every siRNA tested, which is not practical for screening-based experiments. The final way to control for off-target effects is by lowering the siRNA concentration during transfection. 8 Because our siRNA screening sets are preformatted at 25 nM, this analysis was restricted at this concentration. However, we have found that the 25 nM concentration was adequate to maximize intracellular siRNA concentrations and ensure adequate mRNA knockdown of both high-and low-abundance target genes (data not shown). 9, 10 For siRNA studies, there are several choices for a negative control siRNA for a particular gene: a mismatched control, a mutated control, or a nonspecific siRNA such as one directed to luciferase or GFP. 11 However, in the context of genomic scale siRNA screening, it is impractical to have a mismatched or mutated siRNA control for every gene in the genome. To overcome this issue, we used GFP siRNAs as the surrogate negative control for all genes analyzed in a siRNA-based screen. The surrogate GFP siRNA performs in the same manner as a mismatched, mutated (data not shown), or sequenceindependent siRNA control ( Figs. 5 and 7) . Using a single standardized negative control will reduce the off-target phenotypes associated with using several mismatched or mutated control siRNAs. 12 The GFP siRNA sequence was chosen for these studies because it is a sequence not present in the mammalian genome and because luciferase is being used as the target gene for optimization.
It is interesting to note that the luciferase-directed siRNAs were predicted to inhibit luciferase activity by 10%, 70%, and 90%, which tracked well with the phenotype optimization, demonstrated by siRNAs inhibiting the luciferase phenotype by 10%, 50%, and 98%, respectively (Fig. 5A) . The use of several negative control siRNAs, both nonspecific sequences and targets to endogenous genes, is critical to the interpretation of this type of experiment. There is a 10% to 30% variation in luciferase levels across the various negative control siRNAs, whereas none of the siRNAs have an effect on viability. Thus, the 10% to 30% variation (nonspecific effects) of luciferase levels can be described only as off-target phenotypes. The luciferase targeted siRNAs provide the linear range based on a true on-target phenotype (pGL3-Hi) rather than off-target effects (pGL3-Lo, negative controls).
The luciferase-based optimization system is well suited to analyze siRNA efficacy for several reasons. First, luciferase overexpression will generate a large-abundance transcript that is known to be easier to knock down than a low-abundance message. 4 Second, because the luciferase protein has a short half-life in the cell, even a small effect on mRNA levels will translate into a large effect on cellular activity. Finally, the luciferase siRNAs could be working by translational suppression of the luciferase message or acting through a similar mechanism as microRNAs. 5 If the siRNAs cannot only suppress mRNA levels via the RNA-induced silencing complex but also suppress translation, the amount of active protein in the cell would be rapidly reduced and easily detected by the luciferase assay. 13 Over the 72-h transfection period analyzed in these experiments, any of these aforementioned possibilities could reduce luciferase activity more than would be predicted by mRNA or protein knockdown alone.
In testing several human carcinoma cell lines (A549, Hela, MDA-MB-231, and Panc 4.03), it became clear that this assay is applicable to several types of cell lines in culture (Fig. 6A,  B, C, D) . It will be interesting to see if this assay can also be used to optimize siRNA delivery in primary human or stem cell cultures. We have demonstrated that rat UMR cells (data not shown) can be effectively optimized using this system (Tables 1 and 3) , identifying its utility in cell lines from other species. It is interesting to point out the large difference in performance of the lipids in a 384-well format. For example, Oligofectamine was the least toxic lipid used in the analysis but did not always give the best efficacy (Fig. 6E) . In several cases, Dharmafect 4 was the better lipid for siRNA efficacy but in all cell lines was toxic at higher volumes. These data demonstrate the fine line between optimal siRNA transfection and cell viability. Using this 384-well optimization approach, one can control the unpredictable nature of the lipids in a miniaturized format. The ability to separate real phenotypic effects from combinatorial effects of siRNA/lipid complexes is essential to running a high-quality siRNA screen.
Using the luciferase lentivirus approach, we can transduce many cell types with relatively high efficiency, eliminating transfection and expression variability at this step in the optimization process. The utility of this assay is the ability of translating an optimized siRNA experiment into a phenotype-based screen such as cell viability or reporter gene activity, without relying on previously established 96-well optimization procedures. It cannot be assumed that a lipid will perform in the same way in a 96-(data not shown) and 384-well siRNA assay (Fig.  6) . It is likely that different cell lines will grow at different rates in different plate formats depending on the assay. One way this procedure could be improved is running a full-scale growth analysis on each cell line before moving into a 384-well format rather than scaling the cell density by plate surface area as we did in this analysis. This is a variable that will be analyzed in future siRNA optimization screens.
The optimized transfection conditions also translated into robust mRNA knockdown of several endogenous target genes. Testing both SMARTpool and single duplex siRNAs, the optimized transfection conditions in SKOV3 cells resulted in at least 60% and up to 80% knockdown of mRNA levels. The optimized conditions not only translated into significant mRNA knockdown but also reproducible knockdown using multiple independent siRNA duplexes.
In conclusion, this assay can rapidly assess the efficacy of siRNA transfection in a 384-well format, thus obviating the need for mRNA measurement in 384-well plates. This process has illustrated that different lipid reagents, all of which have been claimed by their manufacturer to be highly efficient, can differ by several orders of magnitude from each other in siRNA transfection efficacy. With this assay, siRNA transfection can be dramatically improved from a 2-fold effect using standard conditions to a 50-fold effect after transfection optimization (Fig. 6) . Our previous approach involved optimizing siRNA conditions by maximizing the effect of a control siRNA on the phenotype under study, not on siRNA delivery into the cell or mRNA knockdown. Because assay optimization is a slow and technically difficult process, we believe our viral-based siRNA optimization protocol will improve and accelerate our assay development pipeline by first determining the best siRNA transfection conditions in a phenotypically neutral way (Fig. 8) .
Being flexible to optimize different reagents, cell lines, and assay conditions in a streamlined fashion is an invaluable resource for high-throughput assay development. Using this optimization approach, conditions have been identified and used in 2 phenotypic readouts, including cytokine induction of interleukin-8 secretion (V. Iourgenko, personal communication) and protection of compound-induced apoptosis (data not shown), indicating that this procedure is relevant to biological assay optimization prior to high-throughput siRNA screen development.
